FRONTIER From Research Optoacoustic Novelty To Imaging Established in Routine diagnostics
- Coordinator
- Ithera Medical GmbH, Germany
- Runs
- 1 April 2022 to 31 March 2024
- Status
- Finished
- EU funding
- €2.5m
- Total cost
- €3.6m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190174417
What the project is doing
In the project's own words, from its summary on CORDIS.
Multispectral optoacoustic tomography (MSOT) is an innovative biomedical imaging technology that allows for molecular imaging in deep tissue. This noninvasive technology enables assessment of the concentration and distribution of a variety of clinically important molecules in the body and uniquely delivers information of e.g. oxygenation, inflammation, and fibrotic changes. MSOT has already demonstrated significant scientific and clinical value across a range of diseases and applications, making it a promising tool to diagnose diseases and monitor treatment response.
Despite these early successes, the technology is not yet commercially viable on the broad clinical market and currently remains effectively confined to a research environment. FRONTIER will provide iThera Medical the means to translate an optimized MSOT system (MSOT Frontier) from a research environment to application in routine clinical imaging, thereby providing clinicians worldwide a powerful new diagnostic tool.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Ithera Medical GmbH | Munchen | Germany | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI